esc

Type at least two characters to start searching.

select openesc close

Share

Export Citation

APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journalArticlepeer-review

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia

Santi T.

Clinical and Experimental Vaccine Research

Q3
Published: 2022Citations: 6

Abstract

Purpose: This study was performed to investigate humoral immune response and adverse events upon the heterologous prime-boost with a single dose of the mRNA-1273 vaccine among fully CoronaVac-vaccinated, infection-naïve healthcare workers in Indonesia. Materials and Methods: One hundred twenty-five eligible healthcare workers were recruited from one hospital for this prospective cohort study. Blood collection was conducted twice, i.e., on 7 days before and 28 days after the booster vaccination. The titer of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies was quantified accordingly. The post-vaccination adverse event was recorded for both CoronaVac and mRNA-1273 vaccinations. Any breakthrough infection was monitored during the follow-up period. Wilcoxon matched-pairs signed rank test was used to test differences between groups. Results: A significant increase was observed in the titer of anti-SARS-CoV-2 RBD antibodies upon receiving the mRNA-1273 booster (geometric mean titers of 65.57 and 47,445 U/mL in pre- and post-booster, respectively), supporting the argument to use heterologous prime-boost vaccination to improve the protection against COVID-19 in a high-risk population. The mRNA-1273 vaccine, however, caused a higher frequency of adverse events than the CoronaVac vaccine. Nonetheless, the adverse events were considered minor medical events and temporary as all subjects were not hospitalized and fully recovered. Of note, no breakthrough infection was observed during the follow-up to 12 weeks post-booster. Conclusion: The heterologous prime-boost vaccination of healthcare workers with a single dose of the mRNA-1273 vaccine generated a significant elevation in humoral immune response towards RBD of SARS-CoV-2 and was associated with a higher frequency, but minor and transient, adverse events.

Access to Document

10.7774/cevr.2022.11.2.209

Other files and links

Fingerprint

MedicineSciences
VaccinationSciences
Booster doseSciences
Adverse effectSciences
Booster (rocketry)Sciences
TiterSciences
HeterologousSciences
PopulationSciences
Internal medicineSciences
ImmunologySciences
VirologySciences
AntibodySciences
BiologySciences
PhysicsSciences
GeneSciences
AstronomySciences
Environmental healthSciences
BiochemistrySciences